Clearside Biomedical, Inc., headquartered in Alpharetta, Georgia, specializes in delivering therapies to the back of the eye using a unique suprachoroidal space (SCS) injection platform. The company, which went public in 2016, is developing products like XIPERE and collaborates with partners on other ophthalmic therapies using its SCS Microinjector.
Clearside Biomedical (CLSD) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Clearside Biomedical's actual EPS was -$0.10, beating the estimate of -$0.14 per share, resulting in a 27.38% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
